Alnylam Develops Blood-Based RNAi Monitoring Approach | GenomeWeb

Alnylam Pharmaceuticals this week announced that it has developed a new method for monitoring RNAi activity in blood samples.

According to the company, the approach allows for the “quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid.” Alnylam said it expects to “enable” the use of the technology by academics and out-license it for industry applications.

A license has already been granted to Isis Pharmaceuticals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.